Biotech

Benitec Limited (ASX:BLT) RNAi Patent Update

🕔3/22/2011 1:56:00 PM

Benitec Limited (ASX:BLT) (PINK:BNIKF), a world leader in expressed gene silencing for human therapeutics, today announced further positive progress in its fundamental Graham family patent applications exclusively licensed from CSIRO worldwide for human therapeutics. These patents cover silencing of genes using DNA-directed RNA interference (ddRNAi). Progress on these patent applications further strengthens Benitec's position with regards to both its revenue opportunities from licensing of ddRNAi technology for research use and in the commercialization potential of its ddRNAi-based therapeutics, being developed both in house and for the treatment of chronic and life threatening medical conditions, such as infectious diseases and cancer.

Read Full Article▸

Second US Clinical Study In HIV/AIDS Lymphoma Patients Using Benitec Limited (ASX:BLT) ddRNAi Technology

🕔3/21/2011 10:59:00 AM

Benitec Limited (ASX:BLT) (PINK:BNIKF), a world leader in RNA-based gene silencing for human therapeutics, is pleased to acknowledge that the City of Hope research hospital in Duarte, California is planning to initiate a second small Phase I/II study using Benitec's DNA-directed RNA interference (ddRNAi) technology in lymphoma patients carrying the HIV virus. The aim of the study is to optimize the treatment by modifying a range of clinical parameters.

Read Full Article▸

Mesoblast Limited (ASX:MSB) CEO Named BioSpectrum Asia Person Of The Year 2011

🕔3/17/2011 9:43:00 AM

Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that Chief Executive Officer Professor Silviu Itescu has been named BioSpectrum Asia Pacific Person of the Year 2011. BioSpectrum Asia is the leading Asian life sciences publication.

Read Full Article▸

Mesoblast Limited (ASX:MSB) Release Half Year Financial Report To 31 Dec 2010

🕔2/28/2011 5:17:00 PM

Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today reported its half year results for the period ended 31 December 2010. At the reporting date, Mesoblast recorded funds of $140.6 million but has since nearly doubled its cash reserves to $279 million after an equity purchase by global biopharmaceutical company Cephalon Inc. (NASDAQ:CEPH) that brings its total Mesoblast holding to 19.99%.

Read Full Article▸

Australian Market Report of February 24, 2011: Viralytics (ASX:VLA) Receive Chinese Notice To Grant Patent Of Use Of EVATAK(TM) In Ovarian Cancer

🕔2/24/2011 12:10:55 PM

Australian Market Report of February 24, 2011 includes: Viralytics Limited (ASX:VLA) received a patent granting notice from China regarding the use of EVATAK(TM) as ovarian cancer treatment; Peak Resources Limited (ASX:PEK) reported the remaining assay results from the November-December 2010 RC and diamond drilling campaign; Ferrum Crescent Limited (ASX:FCR) has commenced drilling at the Moonlight Iron Ore Project in South Africa; United Uranium Limited (ASX:UUL) announced that No.1 Institute of Geology and Minerals of Shandong Province received investment approval; Gindalbie Metals Limited (ASX:GBG) announced today that the maiden shipment of iron ore from the Karara Iron Ore Project in Western Australia will occur within two months.

Read Full Article▸

Benitec Limited (ASX:BLT) Hepatitis B RNAi Program With Biomics Biotechnologies Moves To The Next Stage Following Successful Stage 1 Results

🕔2/22/2011 12:33:27 PM

Benitec Limited (ASX:BLT) (PINK:BNIKF) announce that following the success of the first stage of its anti-viral program to develop an RNA interference (RNAi)-based therapy against Hepatitis B virus, conducted in collaboration with China-based Biomics Biotechnologies Co. Ltd, the companies have reached agreement to proceed to the next stage which is designed to develop an RNAi therapeutic to the point of pre-clinical studies in vivo.

Read Full Article▸

Australian Market Report of February 21, 2011: Prima BioMed (ASX:PRR) To Commence Clinical Trial For Ovarian Cancer Immunotherapy Vaccine

🕔2/21/2011 12:21:54 PM

Australian Market Report of February 21, 2011 includes: Prima BioMed Limited (ASX:PRR) will commence the Phrase III clinical trial for what could be the world's first ovarian cancer immunotherapy vaccine; Redstone Resources Limited (ASX:RDS) announced further high grade copper results at the Tollu copper project in Western Australia; Western Desert Resources Limited (ASX:WDR) reported more high-grade iron ore results at Roper Bar Iron Ore Project in the Northern Territory; Canyon Resources Limited (ASX:CAY) updated on accelerated drilling program in Burkina Faso.

Read Full Article▸

Banking & Finance

Read More

Oil Gas & Energy

Read More

Life Sciences

Read More

Social Media

Latest Headlines